Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Consolidated Net Income (2021 - 2025)

Historic Consolidated Net Income for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $18.4 million.

  • Kiniksa Pharmaceuticals International's Consolidated Net Income rose 24523.75% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 14299.03%. This contributed to the annual value of -$43.2 million for FY2024, which is 2848.49% up from last year.
  • Kiniksa Pharmaceuticals International's Consolidated Net Income amounted to $18.4 million in Q3 2025, which was up 24523.75% from $17.8 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Consolidated Net Income high stood at $224.1 million for Q3 2022, and its period low was -$49.5 million during Q1 2021.
  • For the 5-year period, Kiniksa Pharmaceuticals International's Consolidated Net Income averaged around $2.3 million, with its median value being -$12.7 million (2024).
  • Its Consolidated Net Income has fluctuated over the past 5 years, first soared by 83367.27% in 2022, then tumbled by 15562.53% in 2023.
  • Kiniksa Pharmaceuticals International's Consolidated Net Income (Quarter) stood at -$44.1 million in 2021, then skyrocketed by 300.84% to $88.5 million in 2022, then tumbled by 155.63% to -$49.2 million in 2023, then soared by 81.95% to -$8.9 million in 2024, then soared by 307.41% to $18.4 million in 2025.
  • Its Consolidated Net Income stands at $18.4 million for Q3 2025, versus $17.8 million for Q2 2025 and $8.5 million for Q1 2025.